Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Generex Biotechnology Corp. (GNBTQ) Message Board

oops...last part didn't come across. Here it is ag

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 36568
(Total Views: 437)
Posted On: 02/06/2021 5:38:38 PM
Posted By: docj
Re: docj #26276
oops...last part didn't come across. Here it is again:

Here is my synopsis on te vaccines not approved by FDA but cleared for emergency use from small patient sampling’s from 40/60 thousand phase 3 trials, this is a hard ride awakening people.

We expect side effects from mRNA vaccines will become more prevalent over time and the weaknesses of mRNA vaccine technology will be exposed. Efficacy and side effect profiles observed in tightly controlled clinical trials often vary from real-world results, especially when trials are limited in scope and duration for accelerated EUA approval by a desperate FDA. In the case of COVID-19 mRNA vaccine trials, close examination of evidence suggests side effects observed in the clinical trials were downplayed or outright ignored. The best example of this is Bell’s Palsy.

In Pfizer’s trial 4 patients experienced “Bell’s Palsy” with 0 (zero) in the placebo group. In Moderna’s trial 3 patients experienced “Bell’s Palsy” with 1 in the placebo group. The FDA concluded that the “Bell’s Palsy” was not attributable to the vaccines because the event rates were similar to that seen in the general population. This logic is inconsistent with standard data interpretation and risk assessment because “Bell’s Palsy” occurred at a 400% higher rate in Pfizer’s trial and 300% higher rate in Moderna’s trial. Under normal circumstances this might have stopped the trials but under EUA it was ignored. But it gets worse... Bell’s Palsy by definition is temporary facial paralysis that completely resolves. Upon trial conclusion and FDA approval, 3 of the 4 cases in Pfizer’s trial were unresolved and 2 of the 3 cases in Moderna’s trial were unresolved (a combined 71.4% remained unresolved). The true and correct medical diagnosis at the time of FDA approval was facial paralysis. Only after paralysis resolves can it be diagnosed as Bell’s Palsy. It’s deceitful and negligent to label unresolved facial paralysis as Bell’s Palsy and was obviously done to downplay the risk and avoid reporting severe adverse events.

We suspect the facial paralysis could have been caused by non-neutralizing antibodies generated by the mRNA vaccines. Only a very small fraction of total antibodies generated from mRNA vaccines are neutralizing. The vast majority are non-neutralizing and pose a potential risk for harmful off-target binding, side effects, and autoimmunity. mRNA vaccines cannot predict or control antigen processing and presentation (i.e. how the Spike protein will be internalized by antigen processing cells, digested into peptides, processed and loaded onto MHC, and presented to the immune system for antibody production). This is a largely random process and peptides-antibodies can vary with each vaccine and booster and vary from person to person. With Generex’s Ii-Key-SARS-CoV-2 vaccine, we know exactly what peptides are being introduced. We know these peptides are being delivered in original pure form directly to MHC because Ii-Key bypasses the natural antigen processing system. Furthermore, using our computational vaccinology programs, we know our peptide sequences do not exist in the human body and harmful off-target antibody binding is not possible. We don’t use 1791 non neutralizing antibodies that Skew also very harmful Th2 from the very bad spike protein, we use only the best and safest parts, in addition these parts are in all variants and will not make our vaccine obsolete at all.

As far as being late to the vaccine race every single person who gets vaccinated by an MRNA vaccine that does not give longe term memory at all should take our vaccine because we will make them better and we can’t hurt you at all.


(2)
(0)




Generex Biotechnology Corp. (GNBTQ) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us